Ongoing TT-223 Clinical Trials......
Re: The ongoing clinicals for TT-223
Dr. Cruz........" So the clinical development for TT-223+GLP1 (GLP1-INT). We are just currently initiating two Phasel Studys to INCREASE OUR FLEXIBILITY with TT-223. That is being done in Canada. The first one starts on Sept. 29th/07. and the second one will start imediately upon finishing this and by the end of the year we expect to have that Data and then we are going to initiate a Phasell Study with TT-223 with Metformin/TZD Patients, 3 Month Repeat Dose. The previous study was one month, we think 3 months should give us better data, and that is expected to start at the beginning of next year. Once this is initiated we will then initiate a second study with TT-223+Byetta, that is currently in the market."
........TT-223 Stand Alone gets its own Phasell Before GLP1-INT.......or Byetta. As stated before........Now THAT is exciting!! Change in focus with the INT Program has been ongoing for several months in-house preparing for the Clinicals and is almost complete. The TT-223+EGF Phasell showed PROOF OF CONCEPT in Humans with 6 months Efficacy after treatment.
OH ....did I mention that TT-223 Stand Alone has Better Results than either Byetta OR Liraglutide (Novo's STILL UNAPPROVED GLP1 Analogue) did at this stage of the game. Way better when you take into account the Nausea that they both induce in Humans.......whereas TT-223 Does Not have ANY Nausea related adverse events in dosing up to 30mg/kg. THATS HUGE!!
GPP All.